It makes MSB's RA program more attractive to any potential partner as another large competitor has failed and more importantly highlights the failures of "drugs" (side effects) vs MSCs (no side effects).
FDA rejects Lilly RA drug, page-3
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.29 |
Change
0.000(0.00%) |
Mkt cap ! $1.467B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 28 | $1.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.28 | 1535 | 1 |
View Market Depth
| Last trade - 09.41am 06/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |
Day chart unavailable